Meneses-Lorente, Georgina http://orcid.org/0000-0001-8961-0902
Guerini, Elena
Mercier, Francois
Parrott, Neil
Kowalski, Karey
Chow-Maneval, Edna
Buchheit, Vincent
Bergthold, Guillaume
Fox, Elizabeth
Phipps, Alex
Djebli, Nassim
Funding for this research was provided by:
F. Hoffmann-La Roche
Article History
Received: 4 August 2022
Accepted: 8 February 2023
First Online: 8 March 2023
Declarations
:
: G.M-L, E.G., N.P. and V.B. are employees and stockholders of F. Hoffmann-La Roche Ltd. F.M. and G.B. are employees of F. Hoffmann-La Roche Ltd. K.K. was an employee of Ignyta (owned by F. Hoffmann-La Roche Ltd) during the time this work was conducted, and subsequently an employee of Pfizer at the time of manuscript preparation. E. C-M was an employee of Ignyta (owned by F. Hoffmann-La Roche Ltd) during the time this work was conducted, and is now an employee of ORIC Pharmaceuticals. A.P. was an employee of F. Hoffmann-La Roche Ltd during the time this work was conducted, and is now an employee of AstraZeneca. E. F. declares no conflicts of interest. N.D. was an employee of F. Hoffmann-La Roche Ltd during the time this work was conducted, and is now an employee of Luzsana Biotechnology.
: The study was approved by the relevant ethics committees and conducted in accordance with the principles of the Declaration of Helsinki and Good Clinical Practice guidelines.
: Informed consent was obtained from the patients, parents or legal guardians.
: No sensitive identifying patient information is included in this manuscript.